Printer Friendly

VIRAL TESTING SYSTEMS WILL FOCUS ON THE ONLY FDA APPROVED TEST THAT CAN BOTH SCREEN AND CONFIRM FOR HIV

 HOUSTON, May 26 /PRNewswire/ -- Viral Testing Systems Corporation (AMEX: VTS) announced today that it has named Dr. Hermann Mucke as senior vice president of Research and Development. Dr. Mucke was responsible for developing Fluorognost HIV-1 IFA, the only FDA approved test that can both screen and confirm for HIV, and report results within 90 minutes. The FDA recently cleared an IND to initiate clinical trials for Fluorognost HIV-2 IFA, the Fluorognost version for the West African variant of the AIDS virus. The test is exclusively distributed and marketed in the United States and the Western Hemisphere by VTS.
 Dr. Mucke has been director of Research and Development for Waldheim Pharmazeutika/Sanochemia Ges. m.b.H., of Neufeld, Austria since 1987 when he left Sandoz. In May 1992, he was appointed executive director for science and regulatory affairs for Sanochemia. He will continue to serve in these positions. He is also a member of the Austrian Biochemical Society and the Austrian Society for Gene Technology. He earned his Doctorate of Science from the University of Vienna.
 Paul Montle, VTS president and chief executive officer, said, "We are very pleased to have Dr. Mucke join us at VTS. He is a diagnostic expert and highly regarded by the research community in Europe and the United States. We eagerly await any future products his team develops. Dr. Mucke's appointment also further solidifies our agreement with Waldheim/Sanochemia." In February, VTS acquired the rights to distribute all diagnostic test products developed by Waldheim/Sanochemia in the Western Hemisphere, Australia, New Zealand, Taiwan, China, Hong Kong, and certain Middle Eastern countries.
 According to Montle, "It is through Dr. Mucke's steady guidance that VTS has decided to focus on the HIV confirmation testing market. There are about three dozen companies selling HIV tests, but most of them are competing for the HIV screening test market. However, all reactive screening tests need to be confirmed and about 20 percent cannot be resolved by current methods. Since Fluorognost is 99.9 percent accurate and is already FDA-approved, we feel that the top-notch confirmation market is where VTS should be concentrating."
 Montle said that several companies are presently seeking FDA approval for their HIV saliva or urine tests, but will require a highly sensitive backup test, such as Fluorognost, for confirmation in order to be granted FDA authorization. VTS has been approached by several of these companies that it assist them with their FDA requests.
 -0- 5/26/93
 /CONTACT: Edward Williamson of Williamson & Associates, 800-992-6616, for Viral Testing Systems; or Holly Vaughan of Viral Testing Systems, 713-228-1544/
 (VTS)


CO: Viral Testing Systems Corporation ST: Texas IN: MTC SU: PER

WB-OS -- NY042 -- 2502 05/26/93 13:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 26, 1993
Words:450
Previous Article:E-SYSTEMS DECLARES SECOND QUARTER DIVIDEND
Next Article:ARTHUR L. KELLY ELECTED TO DEERE & COMPANY BOARD OF DIRECTORS
Topics:


Related Articles
THERMASCAN STATEMENT ON UNRESOLVED HIV-1 ANTIBODY STATUS
THE JOURNAL OF CLINICAL MICROBIOLOGY REPORTS THAT A NEW FDA-APPROVED AIDS TEST WILL IMPROVE SPECIFICITY OF HIV CONFIRMATORY TESTING
VIROLOGY TESTING SCIENCES, INC. ANNOUNCES NEW HIV-2 CONFIRMATION AND SCREENING TEST
VIRAL TESTING SYSTEMS' JANUARY SALES OF HIV TEST BETTER THAN EXPECTED
VIRAL TESTING SYSTEMS ANNOUNCES THAT THE FDA CLEARS IND FOR ITS HIV-2 AIDS CONFIRMATION TEST
TRAVIS PARTNERS EXERCISES VIRAL TESTING SYSTEMS CORPORATION WARRANTS
VIRAL TESTING SYSTEMS WILL FOCUS ON THE ONLY FDA APPROVED TEST THAT CAN BOTH SCREEN AND CONFIRM FOR HIV; DR. HERMANN MUCKE WILL HEAD R&D
FDA APPROVES FIRST HOME COLLECTION HIV TEST
Digene Receives U.S. FDA Approval for Cytomegalovirus (CMV) Test.
FDA approves new HIV-1 test for laboratories.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters